MILLENDO THERAPEUTICS Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Detroit, MI USA
Total Funding:$112M
Industry:Biotech
Founded:N/A
Lead Investor(s):N/A

Industry Ranking

Estimated Revenue & Financials

  • MILLENDO THERAPEUTICS's estimated annual revenue is currently $5.3M per year.
  • MILLENDO THERAPEUTICS's estimated revenue per employee is $155,000
  • MILLENDO THERAPEUTICS's total funding is $112M.

Employee Data

  • MILLENDO THERAPEUTICS has 34 Employees.
  • MILLENDO THERAPEUTICS grew their employee count by -23% last year.
  • MILLENDO THERAPEUTICS currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Swift Bioscienc...
$7.9M512%N/AN/A
Cerenis Therape...
$2.6M17N/AN/AN/A
Delphinus Medic...
$7.3M47N/AN/AN/A
Cayman Chemical...
$43.4M280N/AN/AN/A
Celsee
$10.1M6567%N/AN/A
Thermo Fisher S...
$108.2M69817%N/AN/A
Strata Oncology
$7.1M4644%N/AN/A
MI Bioresearch
$22M1423%N/AN/A
Neogen Corporat...
N/A1201N/AN/AN/A
MILLENDO THERAP...
$5.3M34-23%N/AN/A
Missing a competitor? Contribute!?
Submit

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing's Syndrome (CS).

keywords:Licensing,Biotechnology,Healthcare,Pharmaceuticals

34

Number of Employees

$5.3M

Revenue (est)

1

Current Jobs

-23%

Employee Growth %

$112M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Pharis MohideenChief Medical OfficerEmail Available
Renee NivalaDirector, Financial Reporting
Jiangyin BaoManager, Analytical Chemistry In Cmc
Thomas HooverSvp, Commercial Strategy
Vivian LinSenior Medical DirectorEmail Available
Lou ArcudiCFOEmail Available
Habib DableMember Board Of Directors
Alicia GoodmanHead Of HrEmail Available
Andrew SpencerSVP Preclinical Research & DevelopmentEmail Available
Raju AlluriManager

MILLENDO THERAPEUTICS News

17-Aug-19 - Millendo Therapeutics Appoints Tamara Joseph as General Counsel and Ryan Zeidan as Chief Development Officer

Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan ...

12-Sep-19 - Financial Review: Zynerba Pharmaceuticals (NASDAQ:ZYNE) vs. Millendo Therapeutics (NASDAQ:MLND)

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is ...

31-Aug-19 - Millendo Therapeutics to Participate in September Investor Conferences

ANN ARBOR, Mich.--(BUSINESS WIRE)--. Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel ...

MILLENDO THERAPEUTICS Executive Hires

DateNameTitleReference
2014-11-13Pharis MohideenChief Medical OfficerArticle
2015-10-02Jeffery M. BrinzaSVP Administration & General CounselArticle
2016-04-15Thomas HooverVP Commercial StrategyArticle
2016-06-24Carol GallagherChairpersonArticle
2016-10-14John KirkVP Regulatory AffairsArticle
2016-11-18Christopher SeiterChief Financial OfficerArticle
2018-06-29Ryan ZeidanSenior Vice President, DevelopmentArticle
2018-11-15Louis ArcudiCFOArticle
2018-12-10Carol GallagherChairmanArticle

MILLENDO THERAPEUTICS Acquisitions

DateCompany NameAmountNotesReference
2018-08-10OvaScienceArticle
2018-12-10OvaScienceArticle